The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared w...
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
About this item
Full title
Author / Creator
Publisher
United States: American Diabetes Association
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Diabetes Association
Subjects
More information
Scope and Contents
Contents
The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and compromise glycemic control. This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec (IDeg), an ultra-long-acting basal insulin.
This 26-week, open-label, treat-to-target trial enrolled adults...
Alternative Titles
Full title
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3609505
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3609505
Other Identifiers
ISSN
0149-5992
E-ISSN
1935-5548
DOI
10.2337/dc12-1668
